SPOTLIGHT: National Stem Cell, Azurel to merge

National Stem Cell is merging with New York-based Azurel, a cosmetic company. National Stem Cell is developing stem cell therapies for diabetes and cardiac injury. Release

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.